Evidence map›Paper›PMID 38478093›Full record

ArticleEuropean journal of clinical pharmacology2024

The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line.

Mustafa Korkmaz, Melek Karakurt Eryılmaz, Mehmet Zahid Koçak, Muhammed Muhiddin Er, Engin Hendem, Aykut Demirkıran, Murat Araz, Mehmet Artaç

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mustafa KorkmazDepartment of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, 42080, Turkey. dr.musstafa@gmail.com.ORCID http://orcid.org/0000-0003-0926-6748
Melek Karakurt EryılmazDepartment of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, 42080, Turkey.ORCID http://orcid.org/0000-0003-2597-5931
Mehmet Zahid KoçakDepartment of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, 42080, Turkey.ORCID http://orcid.org/0000-0003-3085-7964
Muhammed Muhiddin ErDepartment of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, 42080, Turkey.ORCID http://orcid.org/0000-0002-0583-0295
Engin HendemDepartment of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, 42080, Turkey.ORCID http://orcid.org/0000-0001-6970-4733
Aykut DemirkıranDepartment of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, 42080, Turkey.ORCID http://orcid.org/0000-0002-2842-4695
Murat ArazDepartment of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, 42080, Turkey.ORCID http://orcid.org/0000-0002-4632-9501
Mehmet ArtaçDepartment of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, 42080, Turkey.ORCID http://orcid.org/0000-0003-2335-3354
Necmettin Erbakan University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeVascular endothelial growth factor (VEGF) inhibition is one of the cornerstones of treatment in the treatment of metastatic renal cell carcinoma (mRCC). Since RCC is a disease of advanced age and hypertension as a side effect of VEGF receptor inhibitors, beta-blocker use is common in these patients. We aimed to compare the treatment efficacy and survival results in case of concomitant use of these two drugs due to the inhibition of VEGF in beta-blockers.

methodsA total of 121 patients with a diagnosis of mRCC who used sunitinib or pazopanib in first-line therapy were included in the study. These patients were divided into two groups as those using concomitant beta-blockers and those not using them.

resultThe median overall survival (mOS) of the patient using sunitinib or pazopanib and concomitant beta-blocker was 47 (95% CI 29.0-65.0) months, and the mOS of those not using concomitant beta-blocker was 18 (95% CI 8.9-27.1) months (p < 0.001). The median progression-free survival (mPFS) of the patients using sunitinib or pazopanib and concomitant beta-blocker was 20.4 (95% CI 4.5-40.1) months, and the mPFS of those not using it was 11.4 (95% CI 5.9-16.9) months (p = 0.042). Concomitant beta-blocker use was found to be a good prognostic factor for OS in the multivariate analysis (p = 0.029). In the multivariate analysis, concomitant beta-blocker use had a trend towards statistical significance for PFS (p = 0.062).

conclusionConcomitant use of betablockers with sunitinib or pazopanib is associated with longer overall survial and progression free survival.

Indexed as

Adrenergic beta-AntagonistsCarcinoma, Renal CellKidney NeoplasmsReceptors, Vascular Endothelial Growth FactorAdultAgedAged, 80 and overAntineoplastic AgentsFemaleHumansIndazolesMaleMiddle AgedProgression-Free SurvivalPyrimidinesRetrospective StudiesAdrenergic beta-AntagonistsAntineoplastic AgentsIndazolespazopanibPyrimidinesReceptors, Vascular Endothelial Growth FactorSulfonamidesSunitinibBeta-blockerPazopanibRenal cell carcinomaSunitinib

Identifiers

PMID38478093
OpenAlexW4392747738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.